11590 related articles for article (PubMed ID: 10851449)
1. Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer.
Dillman RO; Hurwitz SR; Schiltz PM; Barth NM; Beutel LD; Nayak SK; O'Connor AA
Cancer Biother Radiopharm; 1997 Apr; 12(2):65-71. PubMed ID: 10851449
[TBL] [Abstract][Full Text] [Related]
2. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.
Fisher B; Packard BS; Read EJ; Carrasquillo JA; Carter CS; Topalian SL; Yang JC; Yolles P; Larson SM; Rosenberg SA
J Clin Oncol; 1989 Feb; 7(2):250-61. PubMed ID: 2644399
[TBL] [Abstract][Full Text] [Related]
3. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
Pockaj BA; Sherry RM; Wei JP; Yannelli JR; Carter CS; Leitman SF; Carasquillo JA; Steinberg SM; Rosenberg SA; Yang JC
Cancer; 1994 Mar; 73(6):1731-7. PubMed ID: 8156501
[TBL] [Abstract][Full Text] [Related]
4. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma.
Griffith KD; Read EJ; Carrasquillo JA; Carter CS; Yang JC; Fisher B; Aebersold P; Packard BS; Yu MY; Rosenberg SA
J Natl Cancer Inst; 1989 Nov; 81(22):1709-17. PubMed ID: 2810387
[TBL] [Abstract][Full Text] [Related]
5. In vivo distribution of radio-labeled tumor infiltrating lymphocytes in cancer patients.
Chin Y; Janssens J; Bleus J; Zhang J; Raus J
In Vivo; 1993; 7(1):27-30. PubMed ID: 8504205
[TBL] [Abstract][Full Text] [Related]
6. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
Schwartzentruber DJ; Hom SS; Dadmarz R; White DE; Yannelli JR; Steinberg SM; Rosenberg SA; Topalian SL
J Clin Oncol; 1994 Jul; 12(7):1475-83. PubMed ID: 8021739
[TBL] [Abstract][Full Text] [Related]
7. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.
Yannelli JR; Hyatt C; McConnell S; Hines K; Jacknin L; Parker L; Sanders M; Rosenberg SA
Int J Cancer; 1996 Feb; 65(4):413-21. PubMed ID: 8621219
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
[TBL] [Abstract][Full Text] [Related]
11. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer.
Dillman R; Schiltz P; DePriest C; Barth N; Beutel L; de Leon C; O'Connor A; Nayak S
Cancer Biother Radiopharm; 2004 Dec; 19(6):730-7. PubMed ID: 15665620
[TBL] [Abstract][Full Text] [Related]
13. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
[TBL] [Abstract][Full Text] [Related]
14. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.
Merrouche Y; Negrier S; Bain C; Combaret V; Mercatello A; Coronel B; Moskovtchenko JF; Tolstoshev P; Moen R; Philip T
J Clin Oncol; 1995 Feb; 13(2):410-8. PubMed ID: 7844602
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
Markel G; Cohen-Sinai T; Besser MJ; Oved K; Itzhaki O; Seidman R; Fridman E; Treves AJ; Keisari Y; Dotan Z; Ramon J; Schachter J
Anticancer Res; 2009 Jan; 29(1):145-54. PubMed ID: 19331144
[TBL] [Abstract][Full Text] [Related]
16. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.
Economou JS; Belldegrun AS; Glaspy J; Toloza EM; Figlin R; Hobbs J; Meldon N; Kaboo R; Tso CL; Miller A; Lau R; McBride W; Moen RC
J Clin Invest; 1996 Jan; 97(2):515-21. PubMed ID: 8567975
[TBL] [Abstract][Full Text] [Related]
17. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
19. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
[TBL] [Abstract][Full Text] [Related]
20. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
